Skip to main content

RA Capital Management — Portfolio, Page 8

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
18
Industries
Biotechnology 21Health Care 12Therapeutics 11Medical 9Life Science 7Biopharma 6+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 169192 of 453
MBX Biosciences
August 2024

MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.

Biotechnology · Carmel$63.5M Series C
Outpace Bio
August 2024

Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.

Biotechnology · Seattle$144.0M Series B
Bright Peak Therapeutics
June 2024

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

Biotechnology · Allschwil$90.0M Series C
Interius BioTherapeutics
June 2024

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.

Biopharma · Philadelphia$51.4M Series B
Ajax Therapeutics
May 2024

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Biotechnology · Cambridge$95.0M Series C
Bluejay Therapeutics
May 2024

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Biotechnology · San Mateo$182.0M Series C
Asher Bio
April 2024

Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.

Biotechnology · San Francisco$55.0M Series C
SeLux Diagnostics
April 2024

SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.

Biotechnology · Charlestown$48.0M Series D
ProfoundBio
February 2024

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Biotechnology · Seattle$112.0M Series B
Rampart Bioscience
October 2023

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Biopharma · La Jolla$85.0M Series A
Ventricle Health
October 2023

Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.

Health Care · Greensboro$8.0M Seed
Mariana Oncology
September 2023

Mariana Oncology is a biotechnology research industry.

Bioinformatics · Watertown$175.0M Series B
ExcepGen
August 2023

ExcepGen is solving fundamental underlying problems in drug discovery to create a new generation of therapeutics.

Biopharma · San Francisco$4.0M Seed
Capacity Bio
March 2023

Capacity Bio is a therapeutics company that is focused on mitophagy.

Biotechnology · Palo Alto$35.0M Series A
Cooks Venture
January 2023

Cooks Venture operates as a regenerative pasture-raised chicken and meat company.

Food and Beverage · Decatur$47.7M Venture - Series Unknown
Expansion Therapeutics
January 2023

Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.

Biotechnology · San Diego$6.9M Venture - Series Unknown
Verdiva Bio
January 2025

Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.

Biotechnology · London$411.0M Series A
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post-IPO Equity
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B
Phathom Pharmaceuticals
January 2026

Phathom Pharmaceuticals is a biopharmaceutical company.

Biotechnology · Florham Park$130.0M Post-IPO Equity
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Metagenomi
January 2023

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Artificial Intelligence (AI) · Emeryville$100.0M Series B
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post-IPO Equity
Sidera Bio
December 2025

Sidera Bio harness human genetics, that helps in transformative medicines for patients.

Genetics · Copenhagen$109.0M Series A

Where RA Capital Management invests

Biotechnology21
Health Care12
Therapeutics11
Medical9
Life Science7
Biopharma6

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 18 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Vaxcyte received $632.5M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include MBX Biosciences, Outpace Bio, Bright Peak Therapeutics, Interius BioTherapeutics, Ajax Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →